Skin Cancer Charts Graphs: May 2008

Saturday, May 31, 2008

Fwd: Breast cancer expression of CD163, a macrophage scavenger receptor, is related to early distant recurrence and reduced patient survival.

---------- Forwarded message ----------
From: HubMed - breast cancer <rssfwd@rssfwd.com>
Date: Fri, May 30, 2008 at 1:52 AM
Subject: Breast cancer expression of CD163, a macrophage scavenger receptor, is related to early distant recurrence and reduced patient survival.
To: mesothelioma77@gmail.com

[1]Int J Cancer. 2008 May 27;
Shabo I, Stål O, Olsson H, Doré S, Svanvik J

Cells of the monocyte/macrophage lineage are important for tumour cell migration, invasion and metastasis. Fusion between macrophages and cancer cells in animal models in vitro and in vivo causes hybrids with increased metastatic potential. Primary breast cancer cells were characterized for macrophage antigens to test if phenotypic resemblance to macrophages is related to early distant recurrence. Immunostaining for CD163, MAC387 and CD68 was performed in a breast cancer tissue micro array from 127 patients consequently followed up for a median of 13 years. Tumour-associated macrophages expressed all 3 antigens. The breast cancers expressed CD163 to 48%, MAC387 to 14% while CD68 was not expressed. TGF-beta staining intensity was positively related to both CD163 and MAC387 expression. Expression of CD163 in the cancer cells was compared to their DNA ploidy, Nottingham Histological Grade, TNM-stage, node state, presence of estrogen receptors and occurrence of distant metastases and survival. Cancers of a more advanced histological grade expressed CD163 to a higher extent. Cells expressing MAC387 were more common in cancers with a high proportion of CD163 positive cells. Multivariate analysis showed that expression of the macrophage antigen CD163 in breast cancer cells has a prognostic impact on the occurrence of distant metastases and reduced patient survival time. (c) 2008 Wiley-Liss, Inc.

___
Source: http://www.hubmed.org/display.cgi?uids=18506688
--
Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

Fwd: K-State to host fund-raising event in Earl Woods' honor Saturday - Wichita Business Journal

---------- Forwarded message ----------
From: asbestos cancer - Live Search News <rssfwd@rssfwd.com>
Date: Fri, May 30, 2008 at 1:51 AM
Subject: K-State to host fund-raising event in Earl Woods' honor Saturday - Wichita Business Journal
To: mesothelioma77@gmail.com

Delicate Balance [Wichita] KSU's Leasure Hall closed amid concern over asbestos [Wichita] Former regent named chairman of K-State presidential search committee [Wichita] Harris gets $42M Army contract [Orlando] Eagle Group now part of Lockheed Martin ...

Thu, 29 May 2008 21:36:00 GMT

___
Source: http://wichita.bizjournals.com/wichita/stories/2008/05/26/daily23.html
--
Powered by [4]RssFwd, a service of [5]Blue Sky Factory, Inc

Fwd: Radiographer gender and breast-screening uptake.

---------- Forwarded message ----------
From: HubMed - breast cancer <rssfwd@rssfwd.com>
Date: Fri, May 30, 2008 at 1:52 AM
Subject: Radiographer gender and breast-screening uptake.
To: mesothelioma77@gmail.com

[1]Br J Cancer. 2008 Jun 3; 98(11): 1759-61
Fitzpatrick P, Winston A, Mooney T

BreastCheck, the Irish National Breast Screening Programme, screens women aged 50-64. Radiographer recruitment has been a challenge; doubling of numbers is required for full national expansion; to date females are employed. The aim was to document attitudes to male radiographers and effect on return for subsequent screening. In all 85.8% of a random sample of 2000 women recently screened by BreastCheck completed a postal questionnaire. The commonest reaction women felt they would have if there were a male radiographer was embarrassment; significantly greater among those attending a static unit (45.6%) than mobile (38.4%) and in younger women (46%) than older (38.7%). Nine per cent would not have proceeded if the radiographer was male and 9% would only have proceeded if female chaperone present. In all 17.5% (95% CI 15.7-19.4%) agreed that 'If there were male radiographers I would not return for another screening appointment'; 18.3% were unsure. One-quarter agreed 'if I heard there could be male radiographers it would change my opinion of BreastCheck for the worse'. The proportions agreeing with these statements did not vary significantly by screening unit type, age group, area of residence or insurance status. This is the largest published study to date of this important issue; the correct balance between equality and programme performance must be identified.

___
Source: http://www.hubmed.org/display.cgi?uids=18506178
--
~
Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

Fwd: Risks and benefits of bisphosphonates.

---------- Forwarded message ----------
From: HubMed - breast cancer <rssfwd@rssfwd.com>
Date: Fri, May 30, 2008 at 1:52 AM
Subject: Risks and benefits of bisphosphonates.
To: mesothelioma77@gmail.com

[1]Br J Cancer. 2008 Jun 3; 98(11): 1736-40
Coleman RE

Bone is the most common site for metastasis in cancer and is of particular clinical importance in breast and prostate cancers due to the prevalence of these diseases. Bone metastases result in considerable morbidity and complex demands on health care resources, affecting quality of life and independence over years rather than months. The bisphosphonates have been shown to reduce skeletal morbidity in multiple myeloma as well as a wide range of solid tumours affecting bone by 30-50%. Quite appropriately, these agents are increasingly used alongside anticancer treatments to prevent skeletal complications and relieve bone pain. The use of bisphosphonates in early cancer is also increasingly important to prevent the adverse effects of cancer treatments on bone health. These include ovarian suppression and the use of aromatase inhibitors in breast cancer patients and androgen deprivation therapy in those with prostate cancer. Bisphosphonate strategies, similar to those used to treat postmenopausal osteoporosis, have suggested that bisphosphonates are a safe and effective treatment for the prevention of treatment-induced bone loss. When compared to other cancer therapies, the frequency and severity of adverse events related to bisphosphonate therapy are generally mild and infrequent; thus, the benefits of treatment with any bisphosphonate almost always outweigh the risks. However, renal dysfunction may occasionally occur and over recent years, a new entity, bisphosphonate-associated osteonecrosis of the jaw (ONJ), has been described. The incidence, clinical importance and prevention strategies to minimise the impact of this problem on patients requiring bisphosphonates is discussed.

___
Source: http://www.hubmed.org/display.cgi?uids=18506174
--
~
Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

Friday, May 30, 2008

Fwd: Predictors of breast cancer-related distress following mammography screening in younger women on a family history breast screening programme.

---------- Forwarded message ----------
From: HubMed - breast cancer <rssfwd@rssfwd.com>
Date: Fri, May 30, 2008 at 1:52 AM
Subject: Predictors of breast cancer-related distress following mammography screening in younger women on a family history breast screening programme.
To: mesothelioma77@gmail.com

[1]Psychooncology. 2008 May 27;
Brain K, Henderson BJ, Tyndel S, Bankhead C, Watson E, Clements A, Austoker J,

Objective: This longitudinal study investigated pre-screening factors that predicted breast cancer-specific distress among 1286 women who were undergoing annual mammography screening as part of a UK programme for younger women (i.e., under 50) with a family history of breast cancer.Methods: Women completed questionnaires one month prior to screening, and one and six months after receiving screening results. Factors measured were breast cancer worry, perceived risk, cognitive appraisals, coping, dispositional optimism, and background variables relating to screening history and family history.Results: Pre-screening cancer worry was the most important predictor of subsequent worry, explaining 56/61% and 54/57% of the variance at one and six months follow-up, respectively. Other salient pre-screening predictors included high perceived risk of breast cancer, appraisals of high relevance and threat associated with the family history, and low perceived ability to cope emotionally. Women who had previously been part of the screening programme and those with a relative who had recently died from breast cancer were also vulnerable to longer-term distress. A false positive screening result, pessimistic personality, and coping efforts relating to religion and substance use predicted outcomes of screening at one month follow-up, but were not predictive in the longer-term.Conclusion: Early intervention to ameliorate high levels of cancer-related distress and negative appraisals would benefit some women as they progress through the familial breast screening programme. Copyright (c) 2008 John Wiley & Sons, Ltd.

___
Source: http://www.hubmed.org/display.cgi?uids=18506670
--
Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

Fwd: Analysis of chemotherapy-induced amenorrhea rates by three different anthracycline and taxane containing regimens for early breast cancer.

---------- Forwarded message ----------
From: HubMed - breast cancer <rssfwd@rssfwd.com>
Date: Fri, May 30, 2008 at 1:52 AM
Subject: Analysis of chemotherapy-induced amenorrhea rates by three different anthracycline and taxane containing regimens for early breast cancer.
To: mesothelioma77@gmail.com

[1]Breast Cancer Res Treat. 2008 May 28;
Han HS, Ro J, Lee KS, Nam BH, Seo JA, Lee DH, Lee H, Lee ES, Kang HS, Kim SW

Purpose: Chemotherapy-induced amenorrhea (CIA) by newer taxane-containing regimens was evaluated in early breast cancer (EBC) patients. Methods: A prospective cohort of 122 premenopausal EBC patients participated in a phase III trial of preoperative docetaxel/capecitabine (TX) versus doxorubicin/cyclophosphamide (AC); 34 patients received adjuvant AC followed by paclitaxel (T) and 129 patients received 5-fluorouracil/doxorubicin/cyclophosphamide (FAC). Results: The CIA rate was 90.2% with TX/AC, 73.5% with AC followed by T, and 72.1% with FAC at 1 year (P = 0.002), and 66.7%, 73.3%, and 58.9%, respectively, at 3 years (P = 0.268). At one year, age (P

___
Source: http://www.hubmed.org/display.cgi?uids=18506620
--
~
Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

Fwd: Toxicity of radiotherapy in patients with collagen vascular disease.

---------- Forwarded message ----------
From: HubMed - breast cancer <rssfwd@rssfwd.com>
Date: Fri, May 30, 2008 at 1:52 AM
Subject: Toxicity of radiotherapy in patients with collagen vascular disease.
To: mesothelioma77@gmail.com

[1]Cancer. 2008 May 27;
Lin A, Abu-Isa E, Griffith KA, Ben-Josef E

BACKGROUND.: A diagnosis of collagen vascular disease (CVD) may predispose to radiotherapy (RT) toxicity. The objective of the current study was to identify factors that influence RT toxicity in the setting of CVD. METHODS.: A total of 86 RT courses for 73 patients with CVD were delivered between 1985 and 2005. CVD subtypes include rheumatoid arthritis (RA; 33 patients), systemic lupus erythematosus (SLE; 13 patients), scleroderma (9 patients), dermatomyositis/polymyositis (5 patients), ankylosing spondylitis (4 patients), polymyalgia rheumatica/temporal arteritis (4 patients), Wegener granulomatosis (3 patients), and mixed connective tissue disorders (MCTD)/other (2 patients). Each patient with CVD was matched to 1 to 3 controls with respect to sex, race, site irradiated, RT dose (+/-2 Gray), and age (+/-5 years). RESULTS.: There was no significant difference between CVD patients (65.1%) and controls (72.5%) experiencing any acute toxicity. CVD patients had a higher incidence of any late toxicity (29.1% vs 14%; P = .001), and a trend toward an increased rate of severe late toxicity (9.3% vs 3.7%; P = .079). RT delivered to the breast had increased risk of severe acute toxicity, whereas RT to the pelvis had increased risk of severe acute and late toxicity. RT administered in the setting of scleroderma carried a higher risk of severe late toxicity, whereas RT to SLE patients carried a higher risk of severe acute and late toxicity. CONCLUSIONS.: Although generally well tolerated, RT in the setting of CVD appears to carry a higher risk of late toxicity. RT to the pelvis or in the setting of SLE or scleroderma may predispose to an even greater risk of severe toxicity. These issues should be considered when deciding whether to offer RT for these patients. Cancer 2008. (c) 2008 American Cancer Society.

___
Source: http://www.hubmed.org/display.cgi?uids=18506734
--
~
Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

Tuesday, May 27, 2008

Mesothelioma Cancer an How Lives Are Affected

In this disease, malignant cells develop in the mesothelium, a protective lining that covers super of the length's internal organs. Its surpassingly unconfused site is the pleura (outer lining of the lungs and chest cavity), but it may also occur in the peritoneum (the lining of the abdominal cavity) or the pericardium (a sac that surrounds the heart).

Malignancies involving mesothelial cells in these size cavities are known as malignant mesothelioma, which may be localized or diffuse. Mesothelioma is the word used to describe a cancerous tumor that involves the mesothelial cells of an organ, often the lungs, heart, or abdominal organs.

Mesothelioma is a savvy of cancer that is almost always caused by previous exposure to asbestos Malignant mesothelioma has also been linked to curing radiation using thorium dioxide and zeolite, a silicate in the soil.

Diagnosing mesothelioma is often difficult, because the symptoms are similar to those of a number of other conditions. Diagnosis begins with a review of the patient's medical history. Other symptoms of peritoneal mesothelioma may include bowel obstruction, blood clotting abnormalities, anemia, and fever. Shortness of breath, cough, and suffering in the chest due to an accumulation of fluid in the pleural space are often symptoms of pleural mesothelioma.

Symptoms of peritoneal mesothelioma include weight loss and cachexia, abdominal swelling and aches and due to ascites (a buildup of fluid in the abdominal cavity).

Mesothelioma is diagnosed by pathological examination from a biopsy. Symptoms of mesothelioma may not appear until 20 to 50 years after exposure to asbestos. This is the end of a savvy that usually begins with symptoms that send most people to the doctor: a fluid build-up around the lungs (pleural effusions), shortness of breath, suffering in the chest, or pain or swelling in the abdomen.

Tissue is removed, placed under the microscope, and a pathologist makes a definitive diagnosis, and issues a pathology report. Malignant mesothelioma has a peak incidence 35-45 years after asbestos exposure. Transcendently people with malignant mesothelioma have on worked on jobs where they breathed asbestos.

Malignant mesothelioma is often just called simply Mesothelioma and is a system of lung cancer that is quite rare. Malignant mesothelioma is more direct in men, with a male-to-female ratio of 3:1. Malignant mesothelioma is a rare type of cancer in which malignant cells are found in the sac lining the chest or abdomen. Most malignant mesotheliomas put complex karyotypes, with extensive aneuploidy and rearrangement of much chromosomes. It can also occur in children; however, these cases are not thought to be associated with asbestos exposure.

Exposure to airborne asbestos particles increases one's risk of developing malignant mesothelioma.

Unlike lung cancer, there is no association between mesothelioma and smoking

The need for of radiation therapy in pleural mesothelioma has been shown to curtail pain in the majority of patients that are treated. But unfortunately, the duration of symptom control is short-lived. The 2 surgical procedures used are pleurectomy with decortication and extrapleural pneumonectomy.

Radiation has no effect on survival, but it has caused significant palliation in 50% of patients treated for chest aches and and chest wall metastasis.

Surgical resection has been relied upon because radiation and chemotherapy require been ineffective absolute treatments. Pleurectomy with decortication is a more limited procedure and requires less cardiorespiratory reserve. It involves dissection of the parietal pleura, incision of the parietal pleura, and decortication of the visceral pleura followed by reconstruction. It has a morbidity rate of 25% and a mortality rate of 2%. It is a difficult procedure because the tumor encases the true to form pleura; the local recurrence rate is high.

Sunday, May 25, 2008

Fwd: Randomized and Non-randomized Prospective Controlled Cohort Studies in Matched Pair Design for the Long-term Therapy of Corpus uteri Cancer Patients with a Mistletoe Preparation (Iscador).

---------- Forwarded message ----------
From: HubMed - cancer <rssfwd@rssfwd.com>
Date: Sat, May 24, 2008 at 11:22 PM
Subject: Randomized and Non-randomized Prospective Controlled Cohort Studies in Matched Pair Design for the Long-term Therapy of Corpus uteri Cancer Patients with a Mistletoe Preparation (Iscador).
To: mesothelioma77@gmail.com

[1]Eur J Med Res. 2008 Mar 31; 13(3): 107-20
Grossarth-Maticek R, Ziegler R

Background: Mistletoe preparations such as Iscador are in common use as complementary/anthropo?sophic medications for many cancer indications, particularly for solid cancers. Efficacy of this complementary therapy is still discussed controversially. - Objective: Does the long-term therapy with Iscador show any effect on survival or psychosomatic self-regulation of patients with corpus uteri cancer? - Patients and Methods: Prospective recruitment and long-term follow-up in the following 4 controlled cohort studies. (1) Two randomized matched-pairs studies: corpus uteri cancer patients without (30 pairs) and with distant metastases (26 pairs) that never used any kind of mistletoe therapy were matched for prognostic factors. By pairwise random allocation, one of the patients was suggested mistletoe therapy to be applied by the attending physician. (2) Two non-randomized matched-pairs studies: corpus uteri cancer patients without (103 pairs) and with distant metastases (95 pairs) that already received mistletoe (Iscador) therapy were matched by the same criteria to control patients without Iscador therapy. - Results: Concerning overall survival in the randomized studies, a significant effect in favour of Iscador therapy was present only in the first study, the second showed no evidence for an effect: estimate of the hazard ratio and 95% confidence interval: 0.36 (0.16, 0.82) and 1.00 (0.46, 2.16) respectively. In the non-randomized studies, the results that adjusted for relevant prognostic variables were: 0.41 (0.26, 0.63), and 0.61 (0.39, 0.93). The effect of therapy with Iscador within 12 months on psychosomatic self-regulation as a measure of autonomous coping with the disease shows a significant rise in the Iscador group against the control group in the randomized as well as in the non-randomized study on patients with corpus uteri cancer without metastases: estimate of the median difference and 95% confidence interval: 0.40 (0.15, 0.70) and 0.70 (0.25, 1.15) respectively. - Conclusion: The mistletoe preparation Iscador in these studies has the effect of prolonging overall survival of corpus uteri cancer patients. Psychosomatic self-regulation as a measure of autonomous coping with the disease, rises significantly more under Iscador therapy than under conventional therapy alone.

___
Source: http://www.hubmed.org/display.cgi?uids=18499556
--
~
Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

Fwd: Malignant breast cancer in children: a review of 75 patients.

---------- Forwarded message ----------
From: HubMed - breast cancer <rssfwd@rssfwd.com>
Date: Sat, May 24, 2008 at 11:22 PM
Subject: Malignant breast cancer in children: a review of 75 patients.
To: mesothelioma77@gmail.com

[1]J Surg Res. 2008 Jun 15; 147(2): 182-8
Gutierrez JC, Housri N, Koniaris LG, Fischer AC, Sola JE

OBJECTIVE: To determine incidence trends and outcomes for pediatric patients with malignant breast disease. METHODS: The Surveillance, Epidemiology, and End Results registry was examined for all females 19 years of age and younger diagnosed with a malignant breast tumor between 1973 and 2004. RESULTS: A total of 75 patients with malignant breast tumors were identified. Overall, 14.5% of patients had in situ tumors, and 85.5% had invasive disease. Tumors were classified as being either carcinomas (n = 41, 54.7%) or sarcomas (n = 34, 45.3%). The majority of sarcomatous lesions were phyllodes tumors (n = 29, 85.5%), whereas most carcinomas were of a ductal etiology (n = 19, 46.3%). The age-adjusted incidence of all malignant pediatric breast tumors in 2003 was 0.08 cases per 100,000 people (0.03 carcinoma and 0.06 sarcoma cases per 100,000 people). In the carcinoma group, regionally advanced disease was present in 11 patients (26.8%), whereas only 3 patients (7.3%) presented with metastatic disease. All patients with sarcomatous tumors presented with localized disease. Adjuvant radiation therapy was administered in only 9.8% of carcinomas and 8.8% of sarcomas, and 85.4% of carcinoma patients and 97.1% of sarcoma patients underwent surgical resection for their primary disease. Subgroup analysis revealed 5- and 10-year survival rates of 89.6% for patients with sarcomatous tumors and 63.1% and 54.3% for carcinomas. CONCLUSIONS: Malignant pediatric breast malignancies remain relatively rare. The two most common histologies of breast neoplasms in children are malignant carcinomas followed by sarcomas. Although uncommon, malignant disease must be considered in the differential diagnosis of the pediatric patient with a breast mass.

___
Source: http://www.hubmed.org/display.cgi?uids=18498867
--
Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

Fwd: Methyl-donor nutrients inhibit breast cancer cell growth.

---------- Forwarded message ----------
From: HubMed - breast cancer <rssfwd@rssfwd.com>
Date: Sat, May 24, 2008 at 11:23 PM
Subject: Methyl-donor nutrients inhibit breast cancer cell growth.
To: mesothelioma77@gmail.com

[1]In Vitro Cell Dev Biol Anim. 2008 May 23;
Park CS, Cho K, Bae DR, Joo NE, Kim HH, Mabasa L, Fowler AW

Lipotropes (methyl group containing nutrients, including methionine, choline, folate, and vitamin B(12)) are dietary methyl donors and cofactors that are involved in one-carbon metabolism, which is important for genomic DNA methylation reactions and nucleic acid synthesis. One-carbon metabolism provides methyl groups for all biological methylation pathways and is highly dependent on dietary supplementation of methyl nutrients. Nutrition is an important determinant of breast cancer risk and tumor behavior, and dietary intervention may be an effective approach to prevent breast cancer. Apoptosis is important for the regulation of homeostasis and tumorigenesis. The anti-apoptotic protein Bcl-2 may be a regulatory target in cancer therapy; controlling or modulating its expression may be a therapeutic strategy against breast cancer. In this study, the effects of lipotrope supplementation on the growth and death of human breast cancer cell lines T47D and MCF-7 were examined and found to inhibit growth of both T47D and MCF-7 cells. Furthermore, the ratios of apoptotic cells to the total number of cells were approximately 44% and 34% higher in the lipotrope-supplemented treatments of T47D and MCF-7 cancer cells, respectively, compared with the control treatments. More importantly, Bcl-2 protein expression was decreased by approximately 25% from lipotrope supplementation in T47D cells, suggesting that lipotropes can induce breast cancer cell death by direct downregulation of Bcl-2 protein expression. Cancer treatment failure is often correlated with Bcl-2 protein upregulation. These data may be useful in the development of effective nutritional strategies to prevent and reduce breast cancer in humans.

___
Source: http://www.hubmed.org/display.cgi?uids=18498022
--
Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

Saturday, May 24, 2008

Fwd: Nonvisualization of a Sentinel Lymph Node on Lymphoscintigraphy Requiring Reinjection of Sulfur Colloid in a Patient With Breast Cancer.

---------- Forwarded message ----------
From: HubMed - breast cancer <rssfwd@rssfwd.com>
Date: Fri, May 23, 2008 at 7:59 PM
Subject: Nonvisualization of a Sentinel Lymph Node on Lymphoscintigraphy Requiring Reinjection of Sulfur Colloid in a Patient With Breast Cancer.
To: mesothelioma77@gmail.com

[1]Clin Nucl Med. 2008 Jun; 33(6): 389-390
Teal CB, Brem RF, Rapelyea JA, Akin EA

PURPOSE:: The injection techniques and use of lymphoscintigraphy for sentinel lymph node (SLN) biopsy in breast cancer patients vary. Some do not advocate routine use of lymphoscintigraphy. The purpose of this case report is to illustrate when lymphoscintigraphy should be used. METHODS:: At our institution, we use periareolar intradermal injections of 0.6 mCi Tc-99m sulfur colloid followed by lymphoscintigraphy with reported identification rates greater than 99%. The only patient in our series who did not have a SLN identified had presented after excisional biopsy of an upper outer quadrant cancer. We report the case of another patient who presented after excision of an upper outer quadrant invasive ductal carcinoma and had no evidence of lymphatic drainage on lymphoscintigraphy after the periareolar injections of radioisotope. RESULTS:: Additional injections of 0.4 mCi Tc-99m sulfur colloid were performed lateral to the incision in the upper outer quadrant. On lymphoscintigraphy a SLN was visualized and was subsequently successfully identified intraoperatively. CONCLUSION:: This case report supports the value of lymphoscintigraphy for successful identification of a SLN in a patient with prior surgery. We therefore recommend imaging patients who have had prior breast surgery, particularly excisions in the upper outer quadrant.

___
Source: http://www.hubmed.org/display.cgi?uids=18496442
--
Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

Fwd: Simultaneous thigh muscle metastasis from lung cancer and Escherichia coli gas producing myonecrosis.

---------- Forwarded message ----------
From: HubMed - cancer <rssfwd@rssfwd.com>
Date: Fri, May 23, 2008 at 7:59 PM
Subject: Simultaneous thigh muscle metastasis from lung cancer and Escherichia coli gas producing myonecrosis.
To: mesothelioma77@gmail.com

[1]Skeletal Radiol. 2008 May 22;
Martinez GE, Coursey CA, Dodd L, Martinez S

We present the case of a 41-year-old man with known large cell lung cancer who had undergone left pneumonectomy 7 months prior and who presented with a large intramuscular mass involving the posterior left thigh and upper calf. This thigh mass was ultimately surgically explored, and specimens yielded both Escherichia coli organisms and cells reflecting a skeletal muscle metastasis from the patient's known lung cancer. The patient was also found to have a rectal metastasis from his lung cancer. Intramuscular abscesses produced by gastrointestinal tract flora are a well-known presentation of colon cancer. To our knowledge, this is the first case report of the simultaneous occurrence of a skeletal muscle metastasis and an E. coli abscess in the same anatomic location. We believe the patient's rectal metastasis may have been the intermediate step in this process.

___
Source: http://www.hubmed.org/display.cgi?uids=18496688
--
Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

Fwd: Mammographic density using two computer-based methods in an isoflavone trial.

---------- Forwarded message ----------
From: HubMed - breast cancer <rssfwd@rssfwd.com>
Date: Fri, May 23, 2008 at 7:59 PM
Subject: Mammographic density using two computer-based methods in an isoflavone trial.
To: mesothelioma77@gmail.com

[1]Maturitas. 2008 May 19;
Kataoka M, Atkinson C, Warren R, Sala E, Day NE, Highnam R, Warsi I, Bingham SA

OBJECTIVES: Mammographic density is a useful biomarker of breast cancer risk. Computer-based methods can provide continuous data suitable for analysis. This study aimed to compare a semi-automated computer-assisted method (Cumulus) and a fully automated volumetric computer method (standard mammogram form (SMF)) for assessing mammographic density using data from a previously conducted randomised placebo-controlled trial of an isoflavone supplement. METHODS: Mammograms were obtained from participants in the intervention study. A total of 177 women completed the study. Baseline and follow-up mammograms were digitised and density was estimated using Cumulus (read by two readers) and SMF. Left-right correlation, changes in density over time, and difference between intervention and control groups were evaluated. Changes of density over time, and changes between intervention group and control group were examined using paired t-test and Student's t-test, respectively. RESULTS: Inter-reader correlation coefficient by Cumulus was 0.90 for dense area, and 0.86 for percentage density. Left-right correlation of percent density was lower in SMF than in Cumulus. Among all women, percentage density by Cumulus decreased significantly over time, but no change was seen for SMF percentage density. The intervention group showed marginally significant greater reduction of percent density by Cumulus compared to controls (p=0.04), but the difference became weak after adjustment for baseline percent density (p=0.06). No other measurement demonstrated significant difference between intervention and control groups. CONCLUSIONS: This comparison suggests that slightly different conclusions could be drawn from different methods used to assess breast density. The development of a more robust fully automated method is awaited.

___
Source: http://www.hubmed.org/display.cgi?uids=18495387
--
~
Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

Fwd: LA jury awards $9.7 million in asbestos suit (The Fresno Bee)

---------- Forwarded message ----------
From: Yahoo! News Search Results for asbestos cancer <rssfwd@rssfwd.com>
Date: Fri, May 23, 2008 at 7:59 PM
Subject: LA jury awards $9.7 million in asbestos suit (The Fresno Bee)
To: mesothelioma77@gmail.com

A jury awarded $9.7 million to a Georgia man who said he developed chest cancer decades after he was exposed to asbestos while serving as a Navy machinist's mate aboard the USS Preble in Long Beach.

Fri, 23 May 2008 18:06:27 GMT

___
Source: http://us.rd.yahoo.com/dailynews/rss/search/asbestos+cancer/SIG=11i2bk2ef/*http%3A//www.fresnobee.com/384/story/622490.html
--
Powered by [4]RssFwd, a service of [5]Blue Sky Factory, Inc

Friday, May 23, 2008

Fwd: Endoscopic submucosal dissection for gastrointestinal neoplasms.

---------- Forwarded message ----------
From: HubMed - cancer <rssfwd@rssfwd.com>
Date: Thu, May 22, 2008 at 5:14 PM
Subject: Endoscopic submucosal dissection for gastrointestinal neoplasms.
To: mesothelioma77@gmail.com

[1]World J Gastroenterol. 2008 May 21; 14(19): 2962-7
Kakushima N, Fujishiro M

Endoscopic submucosal dissection (ESD) is an advanced technique of therapeutic endoscopy for superficial gastrointestinal neoplasms. Three steps characterize it: injecting fluid into the submucosa to elevate the lesion, cutting the surrounding mucosa of the lesion, and dissecting the submucosa beneath the lesion. The ESD technique has rapidly permeated in Japan for treatment of early gastric cancer, due to its excellent results of en-bloc resection compared to endoscopic mucosal resection (EMR). Although there is still room for improvement to lessen its technical difficulty, ESD has recently been applied to esophageal and colorectal neoplasms. Favorable short-term results have been reported, but the application of ESD should be well considered by three aspects: (1) the possibility of nodal metastases of the lesion, (2) technical difficulty such as location, ulceration and operator's skill, and (3) organ characteristics.

___
Source: http://www.hubmed.org/display.cgi?uids=18494043
--
Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

Fwd: Extra-nuclear signalling of estrogen receptor to breast cancer cytoskeletal remodelling, migration and invasion.

---------- Forwarded message ----------
From: HubMed - breast cancer <rssfwd@rssfwd.com>
Date: Thu, May 22, 2008 at 5:14 PM
Subject: Extra-nuclear signalling of estrogen receptor to breast cancer cytoskeletal remodelling, migration and invasion.
To: mesothelioma77@gmail.com

[1]PLoS ONE. 2008; 3(5): e2238
Giretti MS, Fu XD, De Rosa G, Sarotto I, Baldacci C, Garibaldi S, Mannella P, Biglia N, Sismondi P, Genazzani AR, Simoncini T

BACKGROUND: Estrogen is an established enhancer of breast cancer development, but less is known on its effect on local progression or metastasis. We studied the effect of estrogen receptor recruitment on actin cytoskeleton remodeling and breast cancer cell movement and invasion. Moreover, we characterized the signaling steps through which these actions are enacted. METHODOLOGY/PRINCIPAL FINDINGS: In estrogen receptor (ER) positive T47-D breast cancer cells ER activation with 17beta-estradiol induces rapid and dynamic actin cytoskeleton remodeling with the formation of specialized cell membrane structures like ruffles and pseudopodia. These effects depend on the rapid recruitment of the actin-binding protein moesin. Moesin activation by estradiol depends on the interaction of ERalpha with the G protein Galpha(13), which results in the recruitment of the small GTPase RhoA and in the subsequent activation of its downstream effector Rho-associated kinase-2 (ROCK-2). ROCK-2 is responsible for moesin phosphorylation. The Galpha(13)/RhoA/ROCK/moesin cascade is necessary for the cytoskeletal remodeling and for the enhancement of breast cancer cell horizontal migration and invasion of three-dimensional matrices induced by estrogen. In addition, human samples of normal breast tissue, fibroadenomas and invasive ductal carcinomas show that the expression of wild-type moesin as well as of its active form is deranged in cancers, with increased protein amounts and a loss of association with the cell membrane. CONCLUSIONS/SIGNIFICANCE: These results provide an original mechanism through which estrogen can facilitate breast cancer local and distant progression, identifying the extra-nuclear Galpha(13)/RhoA/ROCK/moesin signaling cascade as a target of ERalpha in breast cancer cells. This information helps to understand the effects of estrogen on breast cancer metastasis and may provide new targets for therapeutic interventions.

___
Source: http://www.hubmed.org/display.cgi?uids=18493596
--
~
Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

Fwd: Breast stromal enhancement on MRI is associated with response to neoadjuvant chemotherapy.

---------- Forwarded message ----------
From: HubMed - breast cancer <rssfwd@rssfwd.com>
Date: Thu, May 22, 2008 at 5:14 PM
Subject: Breast stromal enhancement on MRI is associated with response to neoadjuvant chemotherapy.
To: mesothelioma77@gmail.com

[1]AJR Am J Roentgenol. 2008 Jun; 190(6): 1630-6
Hattangadi J, Park C, Rembert J, Klifa C, Hwang J, Gibbs J, Hylton N

OBJECTIVE: Cancerous neovascular changes in histologically normal-appearing breast tissue have been shown to increase risk for local recurrence after breast-conserving therapy. However, the imaging characteristics of this tissue have not been well studied. We hypothesized that signal enhancement ratios from dynamic contrast-enhanced breast MRI could be used to analyze the contrast kinetics of microvasculature in breast stroma beyond the tumor margin and that this information can be developed to improve local treatment options. MATERIALS AND METHODS: Signal enhancement ratio analysis of nontumor breast stroma was performed on dynamic contrast-enhanced MRI scans of 42 patients who received neoadjuvant chemotherapy for invasive breast cancer performed before chemotherapy (scan 1) and after one cycle of chemotherapy (scan 2). Stromal signal enhancement ratio values were then correlated to several clinical parameters and to clinical outcome using univariate and multivariate analyses. Median follow-up for the group was 52.1 months. RESULTS: On univariate analysis, factors that were significantly associated (p

___
Source: http://www.hubmed.org/display.cgi?uids=18492917
--
~
Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

Wednesday, May 21, 2008

Fwd: Expression of short-form oncostatin M receptor as a decoy receptor in lung adenocarcinomas.

---------- Forwarded message ----------
From: HubMed - cancer <rssfwd@rssfwd.com>
Date: Wed, May 21, 2008 at 8:29 AM
Subject: Expression of short-form oncostatin M receptor as a decoy receptor in lung adenocarcinomas.
To: mesothelioma77@gmail.com

[1]J Pathol. 2008 Apr 14;
Chen D, Chu CY, Chen CY, Yang HC, Chiang YY, Lin TY, Chiang IP, Chuang DY, Yu CC, Chow KC

Oncostatin M (OSM) is a member of the interleukin-6 (IL-6) family of cytokines, and binds to the OSM receptor (OSMR) to inhibit cancer growth. Four forms of OSMR have been identified: leukemia inhibitory factor receptor (LIFR), OSMRbeta, short-form OSMR (OSMRs) and soluble OSMR (sOSMR). In this study, we examined the type and expression of OSMR in lung adenocarcinomas (LADCs). Expression of OSMR was determined by reverse transcription-polymerase chain reaction (RT-PCR), immunoblotting, immunohistochemistry and confocal immunofluorescent microscopy (CIM). Our results showed that, among the four forms of OSMR, OSMRs was mainly expressed in LADC, and expression level of OSMRs correlated with patient survival. CIM revealed that OSMRs was localized on the cell membrane of LADC cell lines in vitro. OSMRs acts as a decoy receptor by reducing the inhibitory effect of OSM on cell growth. Decrease in OSMRs expression by siRNA increased cell sensitivity to OSM, and ectopic expression of OSMRs reduced cell sensitivity to OSM. These results suggest that expression of OSMRs, which operates as a decoy receptor for OSM, is correlated with disease progression and adverse prognosis in patients with LADC. Copyright (c) 2008 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.

___
Source: http://www.hubmed.org/display.cgi?uids=18491353
--
Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

Fwd: Cumulative effect of five genetic variants on prostate cancer risk in multiple study populations.

---------- Forwarded message ----------
From: HubMed - cancer <rssfwd@rssfwd.com>
Date: Wed, May 21, 2008 at 8:29 AM
Subject: Cumulative effect of five genetic variants on prostate cancer risk in multiple study populations.
To: mesothelioma77@gmail.com

[1]Prostate. 2008 May 19;
Sun J, Chang BL, Isaacs SD, Wiley KE, Wiklund F, Stattin P, Duggan D, Carpten JD, Trock BJ, Partin AW, Walsh PC, Grönberg H, Xu J, Isaacs WB, Zheng SL

BACKGROUND: A strong cumulative effect of five genetic variants and family history on prostate cancer risk was recently reported in a Swedish population (CAPS). We carried out this study to confirm the finding in two U.S. study populations and perform a combined analysis to obtain a more stable estimate of the odds ratio (OR) for prostate cancer. METHODS: We evaluated three SNPs at 8q24 and one SNP each at 17q12 and 17q24.3 in two study populations in the U.S. The first was a hospital-based case-control study population at Johns Hopkins Hospital (JHH), including 1,563 prostate cancer patients and 576 control subjects. The second was the National Cancer Institute Cancer Genetic Markers of Susceptibility (CGEMS) Initiative, including 1,172 prostate cancer patients and 1,157 control subjects. RESULTS: We confirmed a cumulative effect of five risk variants on prostate cancer risk. Based on a total of 5,628 cases and 3,514 controls from JHH, CGEMS, and CAPS, men who carry any combination of 1, 2, 3, and 4 or more of these five risk variants have an estimated OR (95% CI) of 1.41 (1.20-1.67), 1.88 (1.59-2.22), 2.36 (1.95-2.85), and 3.80 (2.77-5.22) for prostate cancer, respectively, compared to men who do not have any of these five risk variants. When family history was included, the cumulative effect was stronger. DISCUSSION: These results provide an important confirmation for the cumulative effect of five genetic risk variants on prostate cancer risk. The more stable OR estimates of the cumulative effect of these six risk factors are a major step toward individual risk characterization for this disease. Prostate (c) 2008 Wiley-Liss, Inc.

___
Source: http://www.hubmed.org/display.cgi?uids=18491292
--
Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

Fwd: Nanotubes pose cancer risk (The Charlotte Observer)

---------- Forwarded message ----------
From: Yahoo! News Search Results for asbestos cancer <rssfwd@rssfwd.com>
Date: Wed, May 21, 2008 at 8:30 AM
Subject: Nanotubes pose cancer risk (The Charlotte Observer)
To: mesothelioma77@gmail.com

Certain types of carbon nanotubes -- microscopic graphite cylinders used in a small but growing number of Space Age applications -- could pose a similar cancer risk as asbestos if inhaled, scientists reported Tuesday. Researchers found that mice injected with nanotubes quickly developed the same biological damage associated with early exposure to asbestos fibers, a known carcinogen. The study ...

Wed, 21 May 2008 10:10:49 GMT

___
Source: http://us.rd.yahoo.com/dailynews/rss/search/asbestos+cancer/SIG=11qaqic5l/*http%3A//www.charlotteobserver.com/162/story/633230.html
--
Powered by [4]RssFwd, a service of [5]Blue Sky Factory, Inc

Wednesday, May 14, 2008

Fwd: Role of MRI in screening, diagnosis and management of breast cancer.

---------- Forwarded message ----------
From: HubMed - breast cancer <rssfwd@rssfwd.com>
Date: Tue, May 13, 2008 at 11:17 PM
Subject: Role of MRI in screening, diagnosis and management of breast cancer.
To: mesothelioma77@gmail.com

[1]Expert Rev Anticancer Ther. 2008 May; 8(5): 811-7
Swayampakula AK, Dillis C, Abraham J

Screening and early diagnosis has an important role in reducing the morbidity and mortality associated with breast cancer. Mammography has an established role and has been approved for routine screening. MRI is an emerging tool and has the highest sensitivity of current breast imaging techniques. Although low specificity and high cost of MRI restricted its use in routine screening, it has been increasingly used in the screening of high-risk individuals, diagnosing occult cases, staging and assessing the response to chemotherapy. MRI-guided techniques, including needle-localization biopsy and vacuum-assisted breast biopsy, have a special role in diagnosis and management. This article focuses on the role of MRI in diagnosis, screening and management of breast cancer, and reviews the current indications for breast MRI.

___
Source: http://www.hubmed.org/display.cgi?uids=18471052
--
Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

Your Finance:

Your Guide, Tips, Strategies And Info

Debts, Loans And Debt Consolidation

Your Guide, Tips, Strategies And Info

Debts and Loan Consolidation

Managing Your Debts

Debt Consolidation Loan

Consolidate Debt Loans: For Better Debt Management

Consolidate Debt Loans: To Eliminate Credit Card Debts

Consolidate Debt Loans

Consolidate Debt Loans For Your School Debts

Debt Consolidation UK